{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:08:35Z","timestamp":1784092115108,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10653-z","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:53:17Z","timestamp":1784087597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ironing Out the Details: Advancing Diagnosis and Treatment of Iron Deficiency in Patients with Heart Failure with Preserved Ejection Fraction \u2013 A Narrative Review"],"prefix":"10.1007","volume":"31","author":[{"given":"Shanshan","family":"Gustafson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Lala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Svetlichnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse K.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankeet S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zara","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"15","key":"10653_CR1","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","volume":"83","author":"M Maddox Thomas","year":"2024","unstructured":"Maddox Thomas M, Januzzi James L, Allen Larry A, Breathett K, Brouse S, Butler J et al (2024) 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction. JACC 83(15):1444\u20131488","journal-title":"JACC"},{"issue":"17","key":"10653_CR2","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS (2023) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118(17):3272\u201387","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10653_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14(10):591\u2013602","journal-title":"Nat Rev Cardiol"},{"key":"10653_CR4","volume":"47","author":"GA Nichols","year":"2023","unstructured":"Nichols GA, Qiao Q, D\u00e9ruaz-Luyet A, Kraus BJ (2023) The clinical burden of newly diagnosed heart failure among patients with reduced, mildly reduced, and preserved ejection fraction. Int J Cardiol Heart Vasc 47:101182","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"3","key":"10653_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251\u2013259","journal-title":"N Engl J Med"},{"issue":"3","key":"10653_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1056\/NEJMoa051530","volume":"355","author":"RS Bhatia","year":"2006","unstructured":"Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A et al (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355(3):260\u2013269","journal-title":"N Engl J Med"},{"issue":"6","key":"10653_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ejhf.497","volume":"18","author":"JM Ter Maaten","year":"2016","unstructured":"Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C et al (2016) Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 18(6):588\u201398","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10653_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00059-022-05123-9","volume":"47","author":"A Deichl","year":"2022","unstructured":"Deichl A, Wachter R, Edelmann F (2022) Comorbidities in heart failure with preserved ejection fraction. Herz 47(4):301\u2013307","journal-title":"Herz"},{"issue":"5","key":"10653_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.amjmed.2012.10.022","volume":"126","author":"JH Gurwitz","year":"2013","unstructured":"Gurwitz JH, Magid DJ, Smith DH, Goldberg RJ, McManus DD, Allen LA et al (2013) Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. Am J Med 126(5):393\u2013400","journal-title":"Am J Med"},{"issue":"11","key":"10653_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","volume":"34","author":"EA Jankowska","year":"2012","unstructured":"Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P (2012) Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34(11):816\u201329","journal-title":"Eur Heart J"},{"issue":"1","key":"10653_CR11","doi-asserted-by":"publisher","first-page":"e001012","DOI":"10.1136\/openhrt-2019-001012","volume":"6","author":"LB Anna","year":"2019","unstructured":"Anna LB, Josephine Lillian W, Nia R, Philippe M, Nick PT, David K (2019) Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart 6(1):e001012","journal-title":"Open Heart"},{"issue":"8","key":"10653_CR12","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ejhf.2879","volume":"25","author":"F Lindberg","year":"2023","unstructured":"Lindberg F, Lund LH, Benson L, Linde C, Orsini N, Carrero JJ et al (2023) Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project. Eur J Heart Fail 25(8):1270\u20131280","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10653_CR13","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.jacc.2006.08.034","volume":"48","author":"JN Nanas","year":"2006","unstructured":"Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG et al (2006) Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48(12):2485\u20132489","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10653_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13453","volume":"20","author":"T Mesquita","year":"2021","unstructured":"Mesquita T, Lin Y-N, Ibrahim A (2021) Chronic low-grade inflammation in heart failure with preserved ejection fraction. Aging Cell 20(9):e13453","journal-title":"Aging Cell"},{"issue":"1","key":"10653_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","volume":"7","author":"S von Haehling","year":"2019","unstructured":"von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD (2019) Iron Deficiency in Heart Failure: An Overview. JACC Heart Fail 7(1):36\u201346","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10653_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.124.068883","volume":"150","author":"M Packer","year":"2024","unstructured":"Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ et al (2024) Redefining Iron Deficiency in Patients With Chronic Heart Failure. Circulation 150(2):151\u2013161","journal-title":"Circulation"},{"issue":"1","key":"10653_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12185-010-0743-1","volume":"93","author":"C Camaschella","year":"2011","unstructured":"Camaschella C, Pagani A (2011) Iron and erythropoiesis: a dual relationship. Int J Hematol 93(1):21\u201326","journal-title":"Int J Hematol"},{"issue":"12","key":"10653_CR18","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","volume":"58","author":"DO Okonko","year":"2011","unstructured":"Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA (2011) Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58(12):1241\u20131251","journal-title":"J Am Coll Cardiol"},{"key":"10653_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.778","author":"J Weerts","year":"2022","unstructured":"Weerts J, Barandiaran Aizpurua MA, Brouwers JHM, Mevenkamp J, Schroen BLM, Knackstedt C et al (2022) Effect of iron deficiency on skeletal muscle metabolism in heart failure with preserved ejection fraction. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehac544.778","journal-title":"Eur Heart J"},{"issue":"7","key":"10653_CR20","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.cardfail.2021.03.010","volume":"27","author":"P Martens","year":"2021","unstructured":"Martens P, Claessen G, Van De Bruaene A, Verbrugge FH, Herbots L, Dendale P et al (2021) Iron deficiency is associated with impaired biventricular reserve and reduced exercise capacity in patients with unexplained dyspnea. J Card Fail 27(7):766\u201376","journal-title":"J Card Fail"},{"issue":"3","key":"10653_CR21","doi-asserted-by":"publisher","first-page":"H585","DOI":"10.1152\/ajpheart.00463.2008","volume":"296","author":"Y Naito","year":"2009","unstructured":"Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T (2009) Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 296(3):H585\u2013H93","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10653_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","volume":"133","author":"G Weiss","year":"2019","unstructured":"Weiss G, Ganz T, Goodnough LT (2019) Anemia of inflammation. Blood 133(1):40\u201350","journal-title":"Blood"},{"issue":"44","key":"10653_CR23","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1093\/eurheartj\/ehz680","volume":"40","author":"HH van der Wal","year":"2019","unstructured":"van der Wal HH, Grote Beverborg N, Dickstein K, Anker SD, Lang CC, Ng LL et al (2019) Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. Eur Heart J 40(44):3616\u201325","journal-title":"Eur Heart J"},{"issue":"4","key":"10653_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","volume":"79","author":"G Masini","year":"2022","unstructured":"Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S et al (2022) Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol 79(4):341\u201351","journal-title":"J Am Coll Cardiol"},{"key":"10653_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.757268","volume":"12","author":"AB Gevaert","year":"2021","unstructured":"Gevaert AB, Mueller S, Winzer EB, Duvinage A, Van de Heyning CM, Pieske-Kraigher E et al (2021) Iron deficiency impacts diastolic function, aerobic exercise capacity, and patient phenotyping in heart failure with preserved ejection fraction: a subanalysis of the OptimEx-Clin study. Front Physiol 12:757268","journal-title":"Front Physiol"},{"issue":"3","key":"10653_CR26","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2019020213","volume":"31","author":"EK Batchelor","year":"2020","unstructured":"Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI (2020) Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol 31(3):456\u2013468","journal-title":"J Am Soc Nephrol"},{"issue":"17","key":"10653_CR27","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79(17):e263\u2013e421","journal-title":"J Am Coll Cardiol"},{"key":"10653_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02315","volume":"10","author":"M Perticone","year":"2019","unstructured":"Perticone M, Zito R, Miceli S, Pinto A, Suraci E, Greco M et al (2019) Immunity, inflammation and heart failure: their role on cardiac function and iron status. Front Immunol 10:2315","journal-title":"Front Immunol"},{"issue":"6","key":"10653_CR29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/ejhf.3237","volume":"26","author":"M Packer","year":"2024","unstructured":"Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ et al (2024) Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure. Eur J Heart Fail 26(6):1298\u20131312","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10653_CR30","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00277-019-03777-w","volume":"98","author":"R Mistry","year":"2019","unstructured":"Mistry R, Hosoya H, Kohut A, Ford P (2019) Iron deficiency in heart failure, an underdiagnosed and undertreated condition during hospitalization. Ann Hematol 98(10):2293\u20132297","journal-title":"Ann Hematol"},{"issue":"10","key":"10653_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA (2023) Heart Failure With Preserved Ejection Fraction: A Review. JAMA 329(10):827\u2013838","journal-title":"JAMA"},{"issue":"4","key":"10653_CR32","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1002\/ehf2.13468","volume":"8","author":"T Bekfani","year":"2021","unstructured":"Bekfani T, Nisser J, Derlien S, Hamadanchi A, Frob E, Dannberg G et al (2021) Psychosocial factors, mental health, and coordination capacity in patients with heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction. ESC Heart Fail 8(4):3268\u201378","journal-title":"ESC Heart Fail"},{"issue":"10","key":"10653_CR33","first-page":"862","volume":"7","author":"A Chandra","year":"2019","unstructured":"Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W et al (2019) Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. JACC: Heart Fail 7(10):862\u2013874","journal-title":"JACC: Heart Fail"},{"key":"10653_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.yjmcc.2015.02.025","volume":"83","author":"B Upadhya","year":"2015","unstructured":"Upadhya B, Taffet GE, Cheng CP, Kitzman DW (2015) Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol 83:73\u201387","journal-title":"J Mol Cell Cardiol"},{"issue":"20","key":"10653_CR35","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF et al (2017) Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol 70(20):2476\u20132486","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10653_CR36","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS et al (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 391(16):1475\u20131485","journal-title":"N Engl J Med"},{"issue":"16","key":"10653_CR37","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M et al (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"2","key":"10653_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"TE-KC Group","year":"2023","unstructured":"Group TE-KC (2023) Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 388(2):117\u2013127","journal-title":"N Engl J Med"},{"issue":"37","key":"10653_CR39","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 44(37):3627\u20133639","journal-title":"Eur Heart J"},{"key":"10653_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.amjcard.2025.06.006","volume":"254","author":"W Alruwaili","year":"2025","unstructured":"Alruwaili W, Ahmad S, Berzingi S, Atti L, Taha A, Thangjui S et al (2025) Clinical Outcomes of Intravenous Iron Therapy in Systolic Heart Failure Patients Receiving SGLT2 Inhibitors. Am J Cardiol 254:5\u201312","journal-title":"Am J Cardiol"},{"issue":"12","key":"10653_CR41","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ejhf.2992","volume":"25","author":"P Marques","year":"2023","unstructured":"Marques P, Matias P, Packer M, Vieira JT, Vasques-N\u00f3voa F, Sharma A et al (2023) Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors. Eur J Heart Fail 25(12):2191\u20138","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10653_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","volume":"85","author":"AS Desai","year":"2025","unstructured":"Desai AS, Vaduganathan M, Claggett BL, Kulac IJ, Jhund PS, Cunningham J et al (2025) Finerenone in Patients With a Recent Worsening Heart Failure Event. JACC 85(2):106\u2013116","journal-title":"JACC"},{"key":"10653_CR43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","author":"M Packer","year":"2024","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V et al (2024) Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"issue":"10456","key":"10653_CR44","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ et al (2024) Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 404(10456):949\u2013961","journal-title":"Lancet"},{"issue":"15","key":"10653_CR45","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK et al (2024) Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med 390(15):1394\u20131407","journal-title":"N Engl J Med"},{"issue":"19","key":"10653_CR46","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1001\/jama.2017.5427","volume":"317","author":"GD Lewis","year":"2017","unstructured":"Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM et al (2017) Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA 317(19):1958\u20131966","journal-title":"JAMA"},{"issue":"3","key":"10653_CR47","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/MIB.0000000000000314","volume":"21","author":"C Gasche","year":"2014","unstructured":"Gasche C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, B\u00fcning C et al (2014) Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis 21(3):579\u201388","journal-title":"Inflamm Bowel Dis"},{"key":"10653_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194448","author":"C Schmidt","year":"2021","unstructured":"Schmidt C, Allen S, Kopyt N, Pergola P (2021) Iron replacement therapy with oral ferric maltol: review of the evidence and expert opinion. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10194448","journal-title":"J Clin Med"},{"issue":"25","key":"10653_CR49","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25):2436\u20132448","journal-title":"N Engl J Med"},{"issue":"11","key":"10653_CR50","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020. Eur Heart J 36(11):657\u201368","journal-title":"Eur Heart J"},{"issue":"10266","key":"10653_CR51","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895\u20131904","journal-title":"Lancet"},{"issue":"10369","key":"10653_CR52","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB et al (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400(10369):2199\u2013209","journal-title":"Lancet"},{"issue":"22","key":"10653_CR53","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1001\/jama.2025.3833","volume":"333","author":"SD Anker","year":"2025","unstructured":"Anker SD, Friede T, Butler J, Talha KM, Placzek M, Diek M et al (2025) Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial. JAMA 333(22):1965\u20131976","journal-title":"JAMA"},{"key":"10653_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ahj.2023.08.005","volume":"266","author":"J Harrington","year":"2023","unstructured":"Harrington J, Mentz RJ, Rockhold FW, Garg J, Butler J, De Pasquale CG et al (2023) Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial. Am Heart J 266:25\u201331","journal-title":"Am Heart J"},{"key":"10653_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03671-1","author":"SD Anker","year":"2025","unstructured":"Anker SD, Karakas M, Mentz RJ, Ponikowski P, Butler J, Khan MS et al (2025) Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03671-1","journal-title":"Nat Med"},{"issue":"2","key":"10653_CR56","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJMcp2305181","volume":"392","author":"A Cannata","year":"2025","unstructured":"Cannata A, McDonagh TA (2025) Heart Failure with Preserved Ejection Fraction. N Engl J Med 392(2):173\u2013184","journal-title":"N Engl J Med"},{"issue":"37","key":"10653_CR57","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","volume":"45","author":"S von Haehling","year":"2024","unstructured":"von Haehling S, Doehner W, Evertz R, Garfias-Veitl T, Derad C, Diek M et al (2024) Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J 45(37):3789\u2013800","journal-title":"Eur Heart J"},{"issue":"5","key":"10653_CR58","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/diagnostics15050540","volume":"15","author":"L Manzi","year":"2025","unstructured":"Manzi L, Buongiorno F, Narciso V, Florimonte D, Forzano I, Castiello DS et al (2025) Acute Heart Failure and Non-Ischemic Cardiomyopathies: A Comprehensive Review and Critical Appraisal. Diagnostics 15(5):540","journal-title":"Diagnostics"},{"issue":"3","key":"10653_CR59","first-page":"345","volume":"18","author":"A Koulaouzidis","year":"2009","unstructured":"Koulaouzidis A, Said E, Cottier R, Saeed AA (2009) Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointestin Liver Dis 18(3):345\u2013352","journal-title":"J Gastrointestin Liver Dis"},{"issue":"6","key":"10653_CR60","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/ejhf.2036","volume":"23","author":"R Sierpinski","year":"2021","unstructured":"Sierpinski R, Josiak K, Suchocki T, Wojtas-Polc K, Mazur G, Butrym A et al (2021) High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. Eur J Heart Fail 23(6):919\u2013932","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10653_CR61","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.cca.2010.07.003","volume":"411","author":"M Franchini","year":"2010","unstructured":"Franchini M, Montagnana M, Lippi G (2010) Hepcidin and iron metabolism: From laboratory to clinical implications. Clin Chim Acta 411(21):1565\u20131569","journal-title":"Clin Chim Acta"},{"issue":"9","key":"10653_CR62","first-page":"872","volume":"133","author":"RJ Mentz","year":"2016","unstructured":"Mentz RJ, Hernandez AF, Berdan LG, Rorick T, O\u2019Brien EC, Ibarra JC et al (2016) Good Clin Pract Guidance Pragmatic Clin Trials Circulation 133(9):872\u2013880","journal-title":"Good Clin Pract Guidance Pragmatic Clin Trials Circulation"},{"issue":"11","key":"10653_CR63","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41569-022-00705-w","volume":"19","author":"MS Usman","year":"2022","unstructured":"Usman MS, Van Spall HGC, Greene SJ, Pandey A, McGuire DK, Ali ZA et al (2022) The need for increased pragmatism in cardiovascular clinical trials. Nat Rev Cardiol 19(11):737\u201350","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"10653_CR64","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/CIRCULATIONAHA.118.034668","volume":"138","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Mentz RJ, Fiuzat M, Butler J, Solomon SD, Ambrosy AP et al (2018) Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. Circulation 138(10):1039\u20131053","journal-title":"Circulation"},{"issue":"10","key":"10653_CR65","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/eurjhf\/hft071","volume":"15","author":"IH Kraai","year":"2013","unstructured":"Kraai IH, Vermeulen KM, Luttik ML, Hoekstra T, Jaarsma T, Hillege HL (2013) Preferences of heart failure patients in daily clinical practice: quality of life or longevity? Eur J Heart Fail 15(10):1113\u20131121","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10653_CR66","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jchf.2023.05.033","volume":"11","author":"JR Golbus","year":"2023","unstructured":"Golbus JR, Gosch K, Birmingham MC, Butler J, Lingvay I, Lanfear DE et al (2023) Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure. JACC Heart Fail 11(11):1521\u20131530","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10653_CR67","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1016\/S2589-7500(22)00111-X","volume":"4","author":"T Ferguson","year":"2022","unstructured":"Ferguson T, Olds T, Curtis R, Blake H, Crozier AJ, Dankiw K et al (2022) Effectiveness of wearable activity trackers to increase physical activity and improve health: a systematic review of systematic reviews and meta-analyses. Lancet Digit Health 4(8):e615\u2013e26","journal-title":"Lancet Digit Health"},{"issue":"6","key":"10653_CR68","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.003878","volume":"10","author":"D Snipelisky","year":"2017","unstructured":"Snipelisky D, Kelly J, Levine JA, Koepp GA, Anstrom KJ, McNulty SE et al (2017) Accelerometer-measured daily activity in heart failure with preserved ejection fraction: clinical correlates and association with standard heart failure severity indices. Circ Heart Fail 10(6):e003878","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10653_CR69","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J et al (2022) The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med 28(4):809\u2013813","journal-title":"Nat Med"},{"issue":"6","key":"10653_CR70","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012204","volume":"18","author":"Y Moayedi","year":"2025","unstructured":"Moayedi Y, Foroutan F, Gao Y, Kim B, De Luca E, Brum M et al (2025) Developments in digital wearable in heart failure and the rationale for the design of TRUE-HF (Ted Rogers understanding of exacerbations in heart failure) Apple CPET study. Circ Heart Fail 18(6):e012204","journal-title":"Circ Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10653-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10653-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10653-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:01:28Z","timestamp":1784091688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10653-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10653"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10653-z","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AL has received speaker honoraria and consulting fees from Novo Nordisk, Boehringer Ingelheim, AstraZenica, Merck, Abiomed, Lexicon, Bayer, Zoll, and Idorsia; research grants from AstraZenica, Merck, Cordio, NovoNordisk; and serves on the Data Safety Monitoring Board for Sequana Medical. JH reports consulting for Novo Nordisk. AB has received research grant support to his institution from National Institutes of Health\/National Heart, Lung, and Blood Institute, National Institutes of Health\/National Institute on Aging, American College of Cardiology Foundation, American Heart Association and the Centers for Disease Control and Prevention and consulting fees from Heart Health Leaders from Bayer, AstraZeneca and Novo Nordisk. APA has received research support through grants from the National Institutes of Health (R01HL173866 and R01AG091005), the Food and Drug Administration (U01FD008704), The American Heart Association, The Permanente Medical Group, Kaiser Permanente Northern California Community Benefits Programs, Garfield Memorial Fund, Abbott Laboratories, Abiomed, Amarin Pharma, Inc., Bayer Pharma AG, Boehringer Ingelheim, Cordio Medical, Edwards Lifesciences LLC, Esperion Therapeutics, Inc., Merck, and Novartis. Consulting for Bristol Meyer Squibb, Bayer Pharma AG, Corstasis, Merck, Novo Nordisk, Pharmacosmos A\/S, Pfizer, scPharma, SQ Innovation, Reprieve Cardiovascular, and VisCardia. All other authors report no relevant disclosures.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"85"}}